novartis ag prexige painkilling drug is rejected by the fda novartis ag said the food and drug administration rejected its painkiller prexige in a decision that had been expected after the drug was withdrawn from the australian market because of side effects the basel switzerland pharmaceutical company said the fda rejected prexige as a once daily treatment for patients suffering from osteoarthritic pain this year prexige was blamed for the deaths of two people in australia and for triggering liver failure that required two others to have liver transplants at an investor event sept novartis chief executive daniel vasella said he didnt expect the drug to be approved in the u s novartis at one time said it hoped prexige could achieve global sales of &# million to &# billion but analysts said that wont be possible without the u s market 
